|
|||||
|
|
Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: A post hoc,pooled analysis from two placebo‐controlled trials |
|
| Authors: | Catherine E. DuBeau Jon D. Morrow Stephen R. Kraus Dana Creanga Tamara Bavendam |
| Affiliation: | 1. University of Massachusetts Medical School and UMassMemorial Medical Center, Worcester, Massachusetts;2. Mount Sinai School of Medicine, New York, New York;3. University of Texas Health Science Center at San Antonio, San Antonio, Texas;4. Consultant to Pfizer, Inc., New York, New York;5. Pfizer, Inc., New York, New York |
| Abstract: | |
| Keywords: | antimuscarinic agents fesoterodine older persons overactive bladder patient‐reported outcomes quality of life randomized controlled trials signs and symptoms tolterodine |